Skip to content

RESEARCH LITERACY / SOURCE NOTES

TB-500 versus thymosin beta-4: check molecular identity

Do not assume a material labelled TB-500 is interchangeable with full-length thymosin beta-4. Establish the exact sequence and modification before applying evidence from one material to another.

Editorial draft · primary sources linked; not independently clinically reviewed.
Editorial update:

What was actually identified?

A 2012 analytical investigation identified Ac-LKKTETQ, an acetylated thymosin beta-4 fragment, in the product it tested. A label name alone therefore cannot establish the molecular identity of another sample.

Why the distinction changes the evidence

Research on thymosin beta-4 ophthalmic solution concerns an eye formulation and a defined study population. It cannot establish that injecting a fragment improves musculoskeletal recovery. Route, formulation and molecule must stay attached to the finding.

What to compare on a document

Look for the explicit sequence, terminal modifications, expected mass, method and tested sample identifier. If the report provides only the label “TB-500”, note the unresolved identity rather than silently assigning the evidence for another molecule.

Ask the issuing laboratory what its identity conclusion covers. A software reader should flag an ambiguity, not resolve it from a supplier’s product title.

What about dosage?

Neither this identity comparison nor an analytical identification paper establishes a human treatment dose. Do not combine a fragment identity result with an unrelated full-length study to create a protocol.

Our compound profile preserves separate human, preclinical and uncertainty sections. Regulatory discussion or advisory consideration is not approval of every material using the name.

All evidence guides →